Abstract: To investigate the importance of the cadmium (Cd) exposure condition in the evaluation of toxic effect on renal function and bone metabolism, six groups of Male Wistar rats were given Cd at respective daily doses of 2, 5, 10, 20, 30 and 60 mgCd/kg (as CdCl 2 ) via a gastric tube for 6 consecutive days a week for 60 weeks. In the groups given a low Cd dose (2, 5 and 10 mgCd/kg), relatively more Cd accumulated in the kidney without liver damage than in the liver. In the high Cd dose groups (20, 30 and 60 mgCd/kg), on the other hand, more Cd accumulated in the liver than in the kidney. The daily intake of Cd dose from the intestinal tract in each experimental group was deduced to be about 0.36%-0.54% of the cumulative dose of oral Cd administration. The daily intake of Cd into the body was estimated as 7, 22, 40, 100, 120, 260 µgCd/kg/day in the experimental groups of 2, 5, 10, 20, 30 and 60 mgCd/kg/day, respectively. Increase of plasma enzyme activity (GOT, GPT) and of urinary enzyme excretion (NAG, AAP, GST), reflecting hepatic damage and renal dysfunction, was found in the high Cd dose groups (30 and 60 mgCd/kg) from the 5th week. Non-CdMT concentration in the kidney was also significantly high in the high Cd dose groups. In the low Cd dose groups (2 and 5 mgCd/kg), although the renal Cd concentration was higher than that of the high Cd dose groups, prominent renal dysfunction and hepatic damage were not observed. Regeneration, vacuolization, and eosinophilic bodies in proximal tubular tissue were mainly observed in the groups subjected to 20, 30 and 60 mgCd/kg administration. Very slight regeneration was also observed in the renal proximal tubular tissue at the 30th week for the 5 mgCd/kg and 10 mgCd/kg groups, and at the 60th week for the 2 mgCd/kg group. Remarkable decrease of bone mineral density at the midpoint of the femur was found in the high Cd dose groups. Also, the decrease in bone mineral density was observed before or after the manifestation of the renal dysfunction, depending on the dose and the duration of Cd administration. Urinary excretion of Pyr, DPyr, and Ca increased and plasma BGP decreased in the higher Cd dose groups. Osteoid volume in the femur tissue was not increased significantly by Cd exposure. Based on these results, it was suggested that Cd exposure caused osteoporotic change. The results of the present study suggested that the toxic effect of Cd on renal function and that on bone metabolism were caused at different times and that renal Cd concentration after long-term oral Cd administration depended on the dose and the duration of Cd exposure.
Introduction
Cadmium (Cd) is a ubiquitous non-essential metal that has a long biological half-life. It is present in food and water and accumulates in human tissues, especially the liver and kidney, with age. Cd is widely used industrially in pigments, plastic stabilizers, electroplating, alloys, nickel-cadmium batteries, and a number of other applications. However, both acute and chronic toxic effects of Cd have been reported in humans and animals. As acute toxic effects of Cd in occupational exposure, respiratory toxicity with dyspnea, coughing, tightness in the chest, acute pulmonary edema, and interstitial pulmonary fibrosis have been reported after inhalation exposure to a high dose of Cd. In laboratory animals, it is well known that acute Cd toxicity produces primarily hepatic and testicular injury. In both occupational and environmental low-level exposure to Cd, renal damage and osteotoxicity are considered to be the major adverse health effects of chronic Cd toxicity in humans and animals. The kidney is thought to be the critical organ in chronic Cd exposure.
In the general population, the major source of daily intake of Cd is food, with a small contribution from water and a negligible contribution from the air to the daily intake [1] [2] [3] [4] [5] [6] . In the limited observations in humans and in animal experiments, the average absorption of Cd from the gastrointestinal tract has been estimated as 1%-8% of the Cd that enters the mucosa from the lumen and actually passes into the body [7] [8] [9] [10] [11] [12] [13] . Factors affecting the absorption and tissue distribution of ingested Cd include the animal species, the chemical form of Cd, the dose, the duration, the age of the animal, and interactions of Cd with various nutrients 1-6, 14, 15) . The early clinical indicators of renal damage due to chronic Cd exposure in humans or animals are tubular proteinuria with increased urinary excretion of low-molecular-weight proteins such as retinal binding protein, β2-microblobulin, and metallothionein (MT); increase of Cd in urine; enzymeuria; glucoseuria; aminoaciduria; and decreased renal tubular reabsorption of phosphorus and calcium. In more advanced cases of Cd toxicity, a urinary excretion pattern similar to that observed in Fanconi's Syndrome with glucosuria, aminoaciduria, and phosphaturia has been reported [16] [17] [18] [19] [20] [21] [22] . Thus, the characteristic feature of Cd-induced toxic renal effects is impairment of the reabsorptive function of the proximal tubules.
It has been suggested that the critical concentration of Cd in the renal cortex, which causes renal tubular dysfunction in 10% of the population, is 200 µg/g with variation from 150-300 µg/g, based on animal studies, a few human studies, and a report by the FAO/WHO Joint Expert Committee on Food Additives 4, [23] [24] [25] [26] [27] . However, this value is controversial and may depend on various factors 5, 14, 15, 27) . Several studies suggest that renal dysfunction may be caused by Cd toxicity at Cd concentrations lower than 200 µg/g. For example, when Cd is administered as Cd-metallothionein (CdMT), the critical concentration for renal dysfunction is as low as 10-12 µg/g [28] [29] [30] [31] [32] [33] . Moreover, it has been reported that the renal toxicity of Cd was not only detoxified by endogenous MT but also caused by Cd ions unbound to MT or exogenous CdMT itself [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . MT, low-molecular-weight metal binding proteins, and MT-like metal binding proteins are found in various foods, and are also present and induced in various organs, including intestinal tissue 44) . CdMT does not show the same absorption characteristics, tissue distribution, or toxicity as inorganic Cd compounds. Some studies suggest that the Cd absorbed into intestinal tissue is mainly bound by MT, and that more Cd is transported to and deposited in the kidney as a result of low-dose oral Cd administration, showing a similar distribution to that after CdMT injection [45] [46] [47] [48] .
On the other hand, Cd is also well known as an important contaminant metal in the cause of Itai-Itai disease, which is characterized mainly by renal dysfunction and osteomalacia, toxic effects induced by long-term daily dietary intake of Cd in the Jinzu river basin in Japan. The toxic effects of Cd on renal function have been suggested as a causal factor of bone pathology in Itai-Itai disease [1] [2] [3] [4] [5] [6] [49] [50] [51] . However, regarding osteomalacia caused by chronic Cd toxicity, it is not clear whether the effect of Cd on bone metabolism is a direct effect of Cd or a secondary effect mediated by nephropathy caused by Cd toxicity 6, [49] [50] [51] [52] [53] . Therefore, to evaluate the extent of Cd effects in the general environment and on human health in particular, a number of factors should be considered.
So far, there have been many experimental studies on chronic Cd toxicity using animal models involving surgical operation, parenteral Cd injection, and drinking water or diet containing Cd [54] [55] [56] . However, with regard to the relationship between the critical Cd concentration for renal dysfunction and bone metabolism, there have been only a few studies using quantitative oral Cd administration to investigate the effects of different dose and the duration of Cd exposure under normal physiological conditions [57] [58] [59] [60] . In addition, it has recently been suggested that acute CdMT injection is not an appropriate model to investigate the mechanism(s) of chronic Cd nephropathy 56) . It has also been pointed out that the preferential renal accumulation of Cd as CdMT may have far-reaching consequences for the risk assessment of Cd. Moreover, it has been suggested that a long-term Cd feeding study is desirable to establish the dose-dependent Cd disposition and to investigate differences in renal toxicity between CdMT and CdCl 2 26, 27, 56-60) . Therefore, to evaluate the effect of chronic Cd toxicity on renal function and bone metabolism under normal physiological conditions, the present study was carried out using the experimental model of quantitative long-term oral Cd administration, considering the importance of the dose, the duration of Cd exposure, and the chemical forms of Cd in the kidney.
Materials and Methods

Animals
Male Wistar strain rats, 6 weeks old, were used, with 5~8 animals in each experimental group. The animals were fed a standard rodent diet (CE-2 diet Nippon CLEA) and water ad libitum, and were kept under pathogen-free conditions at a room temperature of 23 ± 1°C on an alternating 12-hr light/dark cycle. Cd as CdCl 2 at a dose of 2, 5, 10, 20, 30, or 60 mgCd/kg was administered orally through a gastric tube for 6 consecutive days a week for 60 weeks in each experimental group. Control animals were administered distilled water in the same manner for the same period. After the final Cd administration, the animals were placed in metabolic cages to collect urine samples for 24 hours. They were then anesthetized by an intraperitoneal injection of pentobarbital (65 mg/kg). Blood samples were drawn directly from the heart and the animals were killed by exsanguination. Organs including the liver, kidney, brain, heart, lung, spleen, pancreas, and testes were removed immediately after washing out the blood remaining in the organs by perfusion via the injection of ice-cold saline solution. The intestine was also washed with 20 ml of ice-cold saline solution to remove the luminal contents.
Biochemical examination
Enzyme activity levels of GOT, GPT, Glutathione Stransferase (GST) 61) , N-acetyl-D-glucosaminidase (NAG) (NAG test Shionogi kit), gamma GTP, and Aranin aminopeptidase (AAP) (AAP test Shionogi kit) were determined using urinary samples. Glucose, protein, creatinine, and amino acid levels were also determined for samples of plasma and urine. Urinary excretion of Pyridinoline (Pyr) and Deoxypyridinoline (DPyr) 62) and plasma intact-Osteocalcin (BGP: RIA from Biomedical Technologies Inc.) were determined as the indices of bone metabolism. Metallothionein (MT) level was determined by the Cd-Hem method 63) for the samples of liver, kidney, and intestine. Additionally, the amount of Cd unbound by MT (non-CdMT) was calculated by determining CdMT according to the modified method 30, 63) .
Metal analysis
Cd in the liver, kidney, intestine, and various other organs was analyzed by flame or flameless atomic absorption spectrophotometry (Hitachi Zeeman AAS 180 60/80) after tissue digestion with nitric acid, using the standard reference materials (NIST: 1577b Bovine Liver and NIES: Rice Flour Unpolished No. 10-a, b, c).
Bone analysis
Bone mineral density was measured from the radiographic density of the bone using a microdensitometer after photography by Softex x-ray equipment using the standard aluminum scale [64] [65] [66] . Analysis of radiophotographs was performed on a Macintosh computer using the NIH Image program.
Histological examination of osteoid volume in bone tissue
The femur was fixed in 0.5% cyanuric chloride in methanol containing 1% (0.1 M) N-methylmorpholine for 2 days before decalcification in 10% formic acid-formalin 67) . The fixed femur was embedded in paraffin, sectioned serially to about 5 µm thickness and stained with Mayer's hematoxylin and 1% aqueous eosin Y. The ratio of osteoid volume to bone volume was measured by a computer analytical system consisting of Photo Enhancer (Kodak), Adobe Photoshop, and an NIH-image analyzer with a light microscope (Olympus BX40) and a digital camera (Kodak DC40).
Histopathological examination of renal tissue
The femur and kidneys were collected immediately. A portion of kidney was fixed in 10% neutral-buffered formalin solution for at least 24 hr and embedded in paraffin. Fivemicrometer sections were stained with hematoxylin and eosin (HE).
Statistics
The data were expressed as the mean value with standard deviation. The differences among the experimental groups were examined by ANOVA with the PLSD and the Scheffe test at p<0.05. Figure 1 shows the concentration of Cd in various organs after long-term oral Cd administration at different Cd doses. Cd accumulated mainly in the liver and kidney, and Cd concentrations in the liver and kidney increased as the dose and the duration of Cd exposure increased in all experimental groups (Fig. 1) . However, in the low Cd dose groups (2, 5, 10 mgCd/kg), it was observed that Cd concentration in the kidney tended to be higher than that in the high Cd dose groups (20, 30 , and 60 mgCd/kg) within a short period after the start of oral Cd administration. In particular, the renal Cd concentration at 60 weeks in the 2 mgCd/kg group was close to 200 µg/g, which has been suggested as the critical dose of Cd in the kidney. On the other hand, Cd concentration in the liver was higher than that in the kidney in the high Cd dose groups (20, 30 and 60 mgCd/kg) ( Fig. 1) . Table 1 shows the estimated rate of Cd absorption from the intestinal tract into the body at the 5th week and the 10th week after oral Cd administration. The daily intake rate of Cd from the intestinal tract in each experimental group was deduced to be about 0.36%-0.54% of the cumulative dose of oral Cd administration. Namely, the daily intake of Cd into the body was estimated as 7, 22, 40, 100, 120, and 260 µgCd/kg/day in the experimental groups administered with 2, 5, 10, 20, 30, and 60 mgCd/kg/day. Figure 2 shows the Cd concentration in the kidney and the results of clinical examination of the kidney and liver functions. Urinary excretion of enzymes (GST, NAG, AAP, ALP), protein, glucose, and amino acid showed a remarkable increase in the high dose groups (20~60 mgCd/kg) as compared to the control group. In the low Cd dose groups (2 and 5 mgCd/kg), marked increase in urinary enzyme excretion was not observed (Fig. 2) . At that time, the Cd concentration in the kidney was not the same in each experimental group. Although the renal Cd concentration (120 µg/g) in the low Cd dose groups (2 and 5 mgCd/kg) was higher than that in the high Cd dose groups (30 and 60 mgCd/kg), no remarkable increase in urinary enzyme excretion was observed without an increase in GST. When the first positive finding of renal injury (shown as the bar shaded graph) was observed in the high Cd dose groups, the Cd concentration in the kidney was 30~60 µg/g. The urinary enzyme excretion (GST, NAG, AAP, ALP) increased remarkably in the high Cd dose groups, corresponding to the increase in Cd accumulation into the kidney (Fig. 2) . Mean is the average of calculated dose for 5 and 10 weeks. Cumulative rate was calculated as the ratio of total cadmium content in various organs (brain, lungs, heart, liver, kidneys, spleen, pancreas and testes) to the cumulative dose of oral cadmium administration. Although GST was a sensitive marker in the early period, it was not stable. NAG was more stable and was a more useful marker than the other urinary enzymes in the continuous monitoring of excreted urinary enzymes to evaluate renal injury. These results reflect the fact that renal proximal tubular cell injury depended on the process of Cd accumulation in the kidney, which in turn depended on the dose and the duration of Cd administration. On the other hand, hepatic damage occurred at a different time from renal injury (Fig. 2) . The activity of GOT and GPT in plasma, which reflect hepatic damage, significantly increased in the high Cd dose groups (20, 30, 60 mgCd/kg). The increases in GOT and GPT were observed at the same time and after the manifestation of emzymuria in the high Cd dose group (Fig. 2) .
Results
As shown in Fig. 3 and Fig. 4 , MT concentration in the kidney and intestine increased as the dose and exposure duration of oral Cd administration increased in all experimental groups (the liver data is not shown here). Increase in non-CdMT (Cd unbound by MT) was observed in the kidney, liver, and intestine in the high Cd dose groups ( Fig. 3 and Fig. 4 ). In the low Cd dose groups, more Cd in the kidney and intestine existed as CdMT. However the amount of non-CdMT increased in the intestine of the high Cd dose groups (30 and 60 mgCd/kg). When Cd concentration in the kidney reached a level of about 50~100 µg/g, a more prominent increase in non-CdMT was observed ( Fig. 2 and Fig. 3 ). The significant increase in urinary enzyme excretion was related to the increased concentration of nonCdMT in the kidney. When increased urinary excretion of enzymes, protein, amino acid, and Ca was observed in the high Cd dose groups, non-CdMT concentration in the kidney was higher than 10 µg/g. The increase in Cd accumulation in the kidney in low Cd dose groups did not cause the prominent renal dysfunction reflected in the increased urinary excretion of enzymes, protein, glucose, and amino acid ( Fig.  2 and Fig. 3 ).
Histopathological examination of renal tissue revealed mainly morphological changes in proximal tubular cells such as regeneration, eosinophilic bodies, vacuolization, and basophilic change in rats in high Cd dose groups (Fig. 5-A , 5-B, 5-C, and Table 2 ). Regeneration, vacuolization, and eosinophilic bodies in proximal tubular tissue were mainly observed at the 5th and the 10th weeks in the groups subjected to 20, 30 and 60 mgCd/kg administration. Regeneration was also observed in the renal proximal tubular tissue at the 30th week in the 5 mgCd/kg and 10 mgCd/kg groups, and at the 60th week in the 2 mgCd/kg group. These histopathological findings were not observed in the control group. These findings were not in complete accord with the results of clinical examination reflecting renal dysfunction. However, the tendency for the manifestation of positive findings was similar in both examinations of all experimental groups (Fig. 2, Fig. 5 , and Table 2 ). Slight membranous thickening in glomerulus tissue was observed at the 40th week in the 20 mgCd/kg group and at the 10th week in the 60 mgCd/kg group (Unpublished data).
To evaluate the effects of Cd on bone metabolism, the bone mineral density was measured using microdensitometry and image analysis. The bone mineral density at the midpoint of the femur decreased as the Cd exposure dose increased. 
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The decrease in bone mineral density was observed before and after the manifestation of the renal dysfunction as increased urinary excretion of enzymes ( Fig. 2 and Fig. 6 ). In the high Cd dose groups (30 and 60 mgCd/kg), the decrease in bone mineral density was observed at the same time as or before the onset of increased urinary enzyme excretion. On the other hand, in the low Cd dose groups (2-10 mgCd/ kg), the decrease in bone mineral density was observed after the manifestation of renal proximal tubular injury by Cd toxicity. A prominent increase in urinary excretion of Pyr, Dpyr, and Ca (unpublished data), which is a marker of bone resorption, was observed in the high dose groups (20, 30 , and 60 mgCd/kg) (Figs. 6, 7, 8 ). An increase in BGP in plasma was also observed in the 30 mgCd/kg group (Fig.  9) . Fig . 10 shows the relative osteoid volume of the femur tissue after oral Cd administration. Osteoid volume (%) in the experimental groups was lower than that in the control group. However, a tendency for osteoid volume in the distal bone tissue area to increase was observed at the 5th and the 10th weeks in the high Cd dose group (60 mgCd/kg) and at the 3rd and 5th weeks in the low Cd dose groups (2 and 5 mgCd/kg).
Discussion
In the present study, we used the model of quantitative oral Cd administration through a gastric tube to control the dosage of Cd and examined the cumulative rate of Cd absorption into the body, in order to evaluate the effect of Cd under normal physiological conditions. It has been reported that about 60%~80% of absorbed Cd in the body is accumulated into the liver and kidney, and that in the case of CdMT administration, approximately 85% of Cd in CdMT is distributed preferentially in the kidneys 2, 4, 5, 19, 38, 68) . Accordingly, the accumulation rate of Cd against the cumulative dose of Cd administration was estimated as the daily intake of Cd from the intestinal tract based on the ratio of the sum of Cd content in various organs (brain, lungs, liver, kidneys, pancreas, spleen, and testes) against the cumulative administered dose of Cd between the 5th and the 10th week. During this period, Cd concentration in various organs increased linearly after oral Cd administration (Fig. 1) . There was no significant difference in intestinal absorption rate of Cd among the experimental groups in the present study. The rates of Cd absorption from the intestinal tract were about 0.4%~0.5% of the cumulative dose of oral Cd administration. These values were relatively low compared to the values suggested values in previous studies 2, 4, 5, [7] [8] [9] [10] [11] [12] [13] . From these values, the daily intake of Cd from the intestinal tract was calculated for each experimental group. The values for the experimental groups from 2 mgCd/kg to 60 mgCd/ kg were deduced to be from about 7 µgCd/kg/day to 270 µgCd/kg/day, respectively (Table 1) . Under these daily Cd intake conditions, the relationship between renal Cd concentration and renal dysfunction is shown in Fig. 2 . The manifestation of renal cell injury reflected by enzymeuria occurred at different times and at different renal Cd concentrations depending on the condition of Cd accumulation in the kidney (Fig. 2) . In addition, the manifestations of enzymeuria, proteinuria, amino aciduria, and glucoseuria, which reflected renal dysfunction, occurred at different times depending on the accumulation process of Cd in the kidney [15] [16] [17] [18] [19] [20] [21] [22] . The shaded bars in Fig. 2 show the first increased time of urinary excretion of enzymes (NAG, ALP, GST), protein, glucose, and amino acid as the indices of renal dysfunction. In other words, the manifestation of renal dysfunction was not always observed when the renal Cd concentration reached the constant value (200 µg/g) reported previously. It is well known that the kidney is the critical organ in chronic Cd toxicity and the critical concentration in the renal cortex has been suggested to be 200 µg/g, varying from 150~300 µg/g 4, 5, [23] [24] [25] [26] . However, in the present study, the renal dysfunction caused by Cd occurred at different Cd concentrations reflecting the difference in the accumulation process in the kidney, which depended on the dose and the duration of Cd exposure [28] [29] [30] [31] [32] [33] [34] [56] [57] [58] [59] [60] (Fig. 2) . Based on these results, it was clarified that the critical concentration of Cd in the kidney was affected by the conditions of Cd exposure; namely, the dose and the duration of oral Cd administration. Thus, it is suggested that the difference in the Cd accumulation process in the kidney, which depends on the dose and the duration of Cd exposure, is an important factor, in evaluating the chronic effect of Cd toxicity in the case of oral Cd administration, particularly for low Cd exposure dose.
On the other hand, in the low Cd dose groups in which prominent hepatic damage was not found (2, 5 and 10 mgCd/ kg), it was thought that the amount of CdMT leaked from the damaged liver did not cause renal damage and that more Cd accumulated in the kidney without renal damage due to Cd toxicity. In contrast, more Cd was accumulated in the liver in the high Cd dose groups (20, 30 , and 60 mgCd/kg). Increased enzyme activity in urine and plasma reflecting damage of the kidney and liver was found in the high Cd dose groups (Fig. 2) . Based on these results, it is thought that much of the Cd intake in a low Cd exposure dose is bound by MT in intestinal tissue, and CdMT in intestinal tissue is transferred to the kidney selectively. However, it may also be conjectured that when Cd exposure dose is high and Cd is not bound by MT in intestinal tissue, the excess Cd in the intestinal tissue causes intestinal damage and is transferred to the liver where it accumulates, causing injury of hepatic and intestinal tissue as observed in the high Cd dose groups. In fact, non-CdMT concentration in the intestinal tissue was high in the high Cd dose groups (30 and 60 mgCd/kg). The released non-CdMT is transported mainly to the liver and accumulated there, while the CdMT released from the intestinal tissue is transported to the kidney and causes renal damage as exogenous CdMT (Fig. 2 and  Fig. 4 ). In the low dose groups (the groups of 2-10 mgCd/ kg), the renal dysfunction indicated by enzymeuria was found without the hepatic damage indicated by increased enzyme activity of GOT and GPT in plasma. Although the Cd concentration in the kidney reached almost the critical concentration in the lower Cd dose group (2 mgCd/kg), no toxic effects in the kidney or liver were observed 28, [30] [31] [32] [33] [34] [35] . In the high Cd dose group (30 and 60 mgCd /kg group), increased activity of GOT and GPT in plasma was observed, suggesting that the hepatic damage was caused by Cd toxicity (Fig. 2) . Consequently, it was thought that Cd in the liver was transferred to the blood in the form of CdMT and transported to the kidney as exogenous CdMT, which is more toxic than the Cd ion. Moreover, enzymeuria, which reflects renal dysfunction, was also observed (Fig. 2) . Although the concentration of Cd in the kidney was still lower (about 40 µg/g) than the critical concentration (200 µg/g), toxic effects on the kidney and liver were observed in the high dose groups. Enzymuria was observed without increased activity of GOT and GPT in the low dose groups (5, 10 mgCd/kg groups). Although it is suggested that renal cell injury and renal dysfunction were caused by exogenous CdMT resulting from hepatic damage by Cd, Cd did not necessarily cause renal dysfunction. The results of the present study suggest that the Cd distribution in the liver and the kidney resulting from parenteral Cd administration and the consequent toxic effect of Cd were different from those in the case of oral Cd administration with low dose. So far, it has been suggested that CdMT transferred to the blood circulation from the damaged liver is then transferred selectively to the kidney, and that when reabsorbed by proximal tubules, Cd causes damage to proximal tubule cells. However, in the case of oral Cd administration, it is thought that the manifestation of toxic effects of Cd on the liver and the kidney and Cd distribution occurred at different times and at different Cd concentrations depending on the difference in Cd accumulation process caused by the difference in Cd exposure conditions (the Cd exposure dose and duration). On the other hand, based on experiments involving parenteral CdMT administration, it has been suggested that renal dysfunction is caused by the catabolism in the kidney of exogenous CdMT released from the liver into the blood circulation. The results of the present study showed that much more Cd was accumulated in the kidney in the low Cd dose groups without hepatic damage, and renal Cd concentration was much higher than that in the liver. These results suggest that Cd absorbed from the intestinal tissue in the low Cd dose groups is bound by MT in the intestine, then transported in the blood circulation as CdMT, and accumulated in the kidney without the toxic effect of CdMT [45] [46] [47] [48] . In the case of chronic ingestion of Cd at low dose, the amount of CdMT taken up from the intestine and transported to the kidney may not be sufficient to cause renal damage. In the case of long-term oral administration of Cd at low dose, it is thought that the presence and the induction of MT in the intestinal tissue must be considered in order to evaluate Cd distribution and Cd toxicity. The chemical form of Cd in the intestine is an important factor affecting the distribution or accumulation of Cd in the body after intestinal Cd uptake [45] [46] [47] [48] . Although hepatic damage was not observed, enzymeuria reflecting injury of renal proximal tubule cells was observed in the low Cd dose groups (2-10 mgCd/kg groups). The relation between the manifestation of renal damage and that of hepatic damage was not always the same. It was thought that the liver damage and kidney damage caused by Cd toxicity occurred at different times relative to each other depending on the accumulation condition of Cd exposure. In other words, the renal dysfunction was not explained by transfer of CdMT from the damaged liver alone (Fig. 2, 3,  4) . These results suggest that the critical concentration varies from 100~300 µg/g depending on the difference in Cd accumulation process relating to the dose and the duration of Cd exposure 4, 22-24, 26, 59, 60) . In parenteral experiments using CdMT and inorganic Cd, the critical concentration of Cd in the kidney clearly differed between the two forms. Cd as exogenous CdMT is very toxic to the kidney and its critical concentration is much lower than that of inorganic Cd 29) . So far, there is no consensus regarding the exact mechanism of the toxic effects of Cd on proximal tubular cells. Two hypotheses have been suggested to explain this mechanism. One hypothesis, based on experiments involving parenteral administration of CdMT, is that the swelling of mitochondria of brush borders of renal proximal tubule tissue is caused by the toxic effect of CdMT itself during reabsorption of CdMT 28, [32] [33] [34] [35] [36] [37] . Another hypothesis is that CdMT is catabolized by a lysosomal enzyme in proximal tubular tissue during the reabsorption of CdMT, and that renal proximal tubule cells are damaged by the Cd ions released by catabolysm of CdMT 38, 40, 41) . If additional Cd unbound by renal MT is released in the kidney, this excess Cd may produce nephrotoxicity [29] [30] [31] . In cells, this excess Cd may interact with cell membranes, causing lipid peroxidation, and/or may displace essential metals from MT, depriving metalloenzymes of essential cofactors 42, 43) . The exact mechanism by which chronic exposure to Cd produces nephrotoxicity is not known, nor is the reason why chronic exposure to Cd is nephrotoxic, but not acute Cd exposure. In fact, in the examination of the chemical form of Cd in the kidney in this study, the non-CdMT fraction was found to be higher in the higher Cd dose groups. Moreover, urinary excretion of enzymes, protein, and glucose reflecting renal cell damage and renal dysfunction were observed at the time when non-CdMT concentration increased above 13 µg/gtissue in the kidney (Fig. 2 and Fig. 3 ). Based on these results of the present study, it was thought that this Cd not bound to MT might be responsible for the toxic effects of Cd in the kidney. In other words, Cd cytotoxicity was thought to be dependent on the amount of non-CdMT present in renal cells, which is not sequestered by available endogenous MT or glutathione [69] [70] [71] . However, Dorian et al. 71) also suggest that the nephrotoxic effect of CdMT is not due to a higher concentration of Cd in the target cells of the kidney being caused by CdMT than by CdCl 2 administration. In addition, it has been suggested that the tendency of CdMT to concentrate at the site where toxicity occurs (S1 and S2 segments of the proximal tubules) might explain why CdMT is nephrotoxic and CdCl 2 is not. Namely, the reason for the nephrotoxicity of CdMT and inorganic Cd cannot be explained by the attainment of a higher concentration of Cd in the target cells by CdMT than CdCl 2 administration. It has also been suggested that the nephrotoxicity of CdMT is not merely due to renal Cd concentration 72) . Consequently, it is suggested that the two forms of Cd may be differ in their uptake paths into cells and their ability to cause injury inside cells 71) . Dorian et al. have also reported that Cd administered as CdMT is distributed preferentially in the S1 and S2 segments of the proximal tubules, the site of Cd nephrotoxicity, but Cd from CdCl 2 is not 38) . Therefore, it is speculated that the distribution of Cd in the proximal tubules varies depending on the chemical form of Cd administered. Based on these studies, the dose, the duration, the chemical form of Cd in the kidney and intestinal tissue, and the exposure route of Cd must be considered as important factors in evaluating the chronic effects of long-term Cd administration. The CdMT released from the damaged liver is also an important factor in renal damage, according to the results for the high Cd dose groups in the present study [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] . In addition, for oral Cd administration, which was used in the present study, the existence and the induction of MT, metal binding protein, in the tissue of the intestinal tract must be considered as factors that affect the Cd distribution and the onset of toxic effects. In particular, for exposure to a low Cd dose, MT in the intestinal tissue and the amount transported to the kidney are considered important factors that affect the Cd distribution in various organs and the manifestation of toxic effects of Cd.
It has been reported that the cellular effects of Cd toxicity, which begin with formation of pinocytotic vesicles of the luminal surface followed by focal mitochondrial changes, can vary from slight swelling to frank necrosis and swelling 28, 33, 37, [71] [72] [73] [74] [75] . We examined the histopathological changes in renal tissue caused by Cd accumulation. Although renal Cd concentration in the high Cd dose groups (20-60 mg Cd/kg) was 40 µg/g, the histopathological changes such as regeneration, eosinophilic bodies, and vacuolization in the proximal tubule tissue were observed early (at 3~5 weeks after the Cd exposure) 6, 54, 55) . These histopathological findings did not show complete agreement with the positive results of clinical biochemical examination. Nevertheless, the results of the histopathological and the clinical biochemical examinations showed a similar tendency. The histopathological findings were observed after the positive findings of the clinical biochemical examination such as enzymeuria (Fig. 2, Fig. 5 , and Table 2 ). Marked proteinuria, glucosuria, and aminoaciduria were observed in the high Cd dose group (30, 60 mg /kg groups), and histopathological changes in the form of a slight glomerulus membranous thickening were observed with proteinuria and glucoseuria in the high dose groups. However, prominent damage to glomerulus tissue was not observed in the present study. Even though the renal Cd concentration reached 180 µg/g after the Cd exposure in the low Cd dose group at the 60th week, no remarkable findings of histopathological tissue damage or clinical biochemical findings were recognized (Fig. 2, Fig. 5 , and Table 2) .
As for the effect of Cd on bone metabolism, there are many hypotheses, involving the indirect secondary effect of Cd following renal damage caused by Cd toxicity, the direct effect of Cd on bone metabolism, and the effect of Cd on the function of intestinal tract tissue, resulting in renal dysfunction 3, 6, [52] [53] [54] [55] . We examined these possibilities in the present study by the measurement of biochemical indices related to change in bone density, change of osteoid volume and bone metabolism, and examined the effect of Cd on bone metabolism, considering the appearance time of enzymeuria to reflect renal injury and dysfunction [76] [77] [78] [79] [80] . At the 3rd and the 5th week, bone density decreased significantly in the high Cd dose groups according to the increase in dose of Cd exposure. On the other hand, no significant difference was recognized in the 2 mg/kg group (low Cd exposure dose) compared with the control group. With the increase of Cd exposure dose and renal Cd accumulation, the bone mineral density decreased significantly (Fig. 2 and Fig. 6 ). The decrease in bone mineral density of the femur was observed before or after the manifestation of renal injury and dysfunction of proximal tubular tissue due to Cd toxicity. With regard to the decrease in bone mineral density, increased urinary excretion of Pyr, DPyr and Ca, which is a clinical biochemical index of bone absorption, was found in the high Cd dose groups (20-60 mgCd/kg) (Figs. 6, 7, and 8) . On the other hand, the concentration of BGP in plasma, which is an index of bone formation, decreased in the high Cd dose groups (at the 3rd and the 10th week in the 30 mgCd/ kg and 60 mgCd/kg groups, respectively) (Fig. 9) . It was thought that the bone resorption was activated by Cd exposure. Furthermore, in the examination of osteoid volume in femur tissue, no remarkable change in osteoid volume (%) was recognized in the tissue of the whole femur. However, a tendency for osteoid volume to increase in the bone end tissue of the femur (distal bone tissue area) was recognized in the 60 mgCd/kg group (Fig. 10) . Based on these results, it was thought that osteoporotic bone changes were caused by Cd, because decrease in bone mineral density, promotion of bone resorption, and decrease in bone formation were produced by chronic Cd intake in the present study 77, 80) . Interestingly, there was a tendency for osteoid volume in the 2 mgCd/kg and 5 mgCd/kg groups to increase without renal injury and for the bone metabolism to be activated compared with that in the control group. Based on these results, it was thought that bone metabolism was stimulated by exposure to a low Cd dose without remarkable activation and renal damage. Comparing the bone metabolism disorder and the appearance time of renal dysfunction, it was thought that both relate to the difference in Cd accumulation process depending on the Cd exposure condition. The manifestation of decrease in bone mineral density was also observed before or after the appearance of renal dysfunction. In the 10 mgCd/ kg and 20 mgCd/kg groups, the decrease in bone mineral density occurred after the renal dysfunction. In other words, compared to the appearance of renal dysfunction, the effect of Cd exposure on bone metabolism, was found soon after Cd exposure in the high Cd dose groups (30 and 60 mgCd/ kg). On the other hand, in the low Cd dose groups (2-10 mgCd/kg), bone metabolism disorder occurred after the appearance of renal dysfunction. Thus, it was thought that the Cd exposure condition is also important in the evaluation of whether the effect of Cd on bone metabolism is direct or indirect, as in the case of renal dysfunction.
In the present study, we considered the importance of difference in the Cd exposure condition and examined the effect of Cd on renal function and bone metabolism using the experimental model of quantitative oral Cd administration. The results indicated that the manifestation of renal dysfunction did not occur in the conventionally accepted manner. In other words, even if the renal Cd concentration reached a critical Cd level, such as the value of 200 µg/g suggested previously, renal damage was not manifested at that renal Cd concentration. The renal dysfunction caused by Cd toxicity occurred at different renal Cd concentrations depending on the process of Cd accumulation. Accordingly, it was thought that the critical concentration also depends on the Cd accumulation condition. In addition, it was thought that the effect of Cd on bone metabolism depends on the Cd exposure condition, as well as the effect of Cd on renal function.
In conclusion, it is important to fully consider the difference in Cd exposure condition (the dose, the duration, and the route of Cd exposure) when evaluating the risks of Cd exposure. Itai-Itai disease has been recognized as a result of chronic Cd exposure, characterized mainly by renal dysfunction and bone metabolism disorder, and has been observed among elderly productive women [2] [3] [4] [5] . Therefore, detailed investigation in female rats at low levels of Cd dose, considering sex difference, aging, and nutritional factors, is needed to clarify the mechanism of Cd toxicity and the maximum safe level of daily Cd intake 4, 26, 27) .
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